文献速递生殖医学

儿童、青少年及年轻成人霍奇金淋巴瘤幸存者的生殖能力:综述

Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review.
PubMed 文献 · Hum Reprod Update · 2023-01-01

本文为叙述性综述,检索PubMed和EMBASE,纳入75篇关于25岁前确诊霍奇金淋巴瘤幸存者生殖指标的研究。女性早发性卵巢功能不全发生率为6-34%(中位9%),男性治疗后无精子症高发(33-100%,中位75%)。生殖能力受损与累积化疗剂量高及盆腔放疗相关,幸存者应接受生育咨询并考虑生育力保存。

要点

  • 女性霍奇金淋巴瘤幸存者早发性卵巢功能不全发生率为6-34%(中位9%),卵巢储备减退常见。
  • 男性幸存者治疗后无精子症发生率为33-100%(中位75%),但部分可恢复。
  • 生殖能力受损与累积化疗剂量高及盆腔放疗相关,应进行生育咨询并考虑生育力保存。

核心结论

  • 本综述证实霍奇金淋巴瘤治疗对性腺功能有负面影响,年轻幸存者应接受未来生殖生活咨询,并应考虑生育力保存。
  • 当前证据水平不足,需要更多关于霍奇金淋巴瘤及(当前)治疗方案对生殖功能影响的试验。
  • 作者基于本综述提出关于可评估的生殖标志物及(重复)测量时机的推荐。

研究设计与样本

  • 叙述性综述,检索PubMed和EMBASE中评估诊断时年龄<25岁的男性和女性霍奇金淋巴瘤幸存者生育力的文章。
  • 最终纳入75篇报告儿童或青少年霍奇金淋巴瘤幸存者生殖标志物的文章。
  • 因研究间存在显著异质性且缺乏对照组,无法进行Meta分析,结果以描述性方式呈现,未单独评估研究质量。

主要发现

  • 41篇论文报告了5057例女性霍奇金淋巴瘤幸存者,早发性卵巢功能不全发生率为6-34%(中位9%;7项研究)。
  • 女性卵巢储备减退或卵巢功能受损常见:抗苗勒管激素(AMH)低为55-59%(中位57%;2项研究),FSH升高为17-100%(中位53%;7项研究),大多数幸存者月经周期规律。
  • 51项研究评估了1903例男性霍奇金淋巴瘤幸存者的生育力,治疗后无精子症高度流行(33-100%;中位75%;29项研究),关于精液恢复的报告至治疗后12年。
  • 男性FSH常升高伴抑制素B低:FSH升高为0-100%(中位51.5%;26项研究),抑制素B低为19-50%(中位45%;3项研究);LH和睾酮水平受影响较不明显(LH升高0-57%,中位17%;21项研究;睾酮低0-43%,中位6%;15项研究)。
  • 两性中生殖能力受损与累积化疗药物剂量较高及盆腔放疗相关;治疗前异常标志物提示疾病本身也可能负面影响生殖功能(女性:AMH<p10为9%;1项研究;男性:无精子症0-50%;中位10%;6项研究)。

关键数值与推荐

  • 女性早发性卵巢功能不全发生率6-34%(中位9%;7项研究)。
  • 女性AMH低55-59%(中位57%;2项研究),FSH升高17-100%(中位53%;7项研究)。
  • 男性治疗后无精子症33-100%(中位75%;29项研究),FSH升高0-100%(中位51.5%;26项研究),抑制素B低19-50%(中位45%;3项研究)。
  • 男性LH升高0-57%(中位17%;21项研究),睾酮低0-43%(中位6%;15项研究)。
  • 治疗前女性AMH<p10为9%(1项研究),男性无精子症0-50%(中位10%;6项研究)。

临床怎么用

  • 作者认为年轻霍奇金淋巴瘤幸存者应接受关于未来生殖生活的咨询,并应考虑生育力保存。
  • 作者提出关于可评估的生殖标志物及(重复)测量时机的推荐。

局限性

  • 研究间存在显著异质性且缺乏对照组,因此无法进行Meta分析。
  • 未单独评估研究质量。
  • 长期随访数据有限。
  • 关于幸存者期间实现妊娠机会的报告令人安心,但研究有其局限性且结果难以评估。
  • 当前证据水平不足,需要更多关于霍奇金淋巴瘤及(当前)治疗方案对生殖功能影响的试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Owing to a growing number of young and adolescent Hodgkin lymphoma (HL) survivors, awareness of (long-term) adverse effects of anticancer treatment increases. The risk of impaired reproductive ability is of great concern given its impact on quality of life. There is currently no review available on fertility after childhood HL treatment. OBJECTIVE AND RATIONALE: The aim of this narrative review was to summarize existing literature on different aspects of reproductive function in male and female childhood, adolescent, and young adult HL survivors. SEARCH METHODS: PubMed and EMBASE were searched for articles evaluating fertility in both male and female HL survivors aged <25 years at diagnosis. In females, anti-Müllerian hormone (AMH), antral follicle count, premature ovarian insufficiency (POI), acute ovarian failure, menstrual cycle, FSH, and pregnancy/live births were evaluated. In males, semen-analysis, serum FSH, inhibin B, LH, testosterone, and reports on pregnancy/live births were included. There was profound heterogeneity among studies and a lack of control groups; therefore, no meta-analyses could be performed. Results were presented descriptively and the quality of studies was not assessed individually. OUTCOMES: After screening, 75 articles reporting on reproductive markers in childhood or adolescent HL survivors were included. Forty-one papers reported on 5057 female HL survivors. The incidence of POI was 6-34% (median 9%; seven studies). Signs of diminished ovarian reserve or impaired ovarian function were frequently seen (low AMH 55-59%; median 57%; two studies. elevated FSH 17-100%; median 53%; seven studies). Most survivors had regular menstrual cycles. Fifty-one studies assessed fertility in 1903 male HL survivors. Post-treatment azoospermia was highly prevalent (33-100%; median 75%; 29 studies). Long-term follow-up data were limited, but reports on recovery of semen up to 12 years post-treatment exist. FSH levels were often elevated with low inhibin B (elevated FSH 0-100%; median 51.5%; 26 studies. low inhibin B 19-50%; median 45%; three studies). LH and testosterone levels were less evidently affected (elevated LH 0-57%, median 17%; 21 studies and low testosterone 0-43%; median 6%; 15 studies). In both sexes, impaired reproductive ability was associated with a higher dose of cumulative chemotherapeutic agents and pelvic radiotherapy. The presence of abnormal markers before treatment indicated that the disease itself may also negatively affect reproductive function (Females: AMH<p10 9%; one study and Males: azoospermia 0-50%; median 10%; six studies). Reports on chance to achieve pregnancy during survivorship are reassuring, although studies had their limitations and the results are difficult to evaluate. In the end, a diminished ovarian reserve does not exclude the chance of a live birth, and males with aberrant markers may still be able to conceive. WIDER IMPLICATIONS: This review substantiates the negative effect of HL treatment on gonadal function and therefore young HL survivors should be counseled regarding their future reproductive life, and fertility preservation should be considered. The current level of evidence is insufficient and additional trials on the effects of HL and (current) treatment regimens on reproductive function are needed. In this review, we make a recommendation on reproductive markers that could be assessed and the timing of (repeated) measurements.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Drechsel KCE, Pilon MCF, Stoutjesdijk F, et al. Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review. Hum Reprod Update. 2023. PMID: 36779325. doi:10.1093/humupd/dmad002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。